Drugstars ApS - CVR: 36893974

2020, DKK

29.06.2021

Bruttoresultat

-2.069'

Primær drift

-7.564'

Årets resultat

-6.950'

Aktiver

5.246'

Kortfristede aktiver

5.176'

Egenkapital

-359'

Afkastningsgrad

-144 %

Soliditetsgrad

-7 %

Likviditetsgrad

166 %

Resultat

29.06.2021

Årsrapport	2020 29.06.2021	2019 01.05.2020	2018 08.04.2019	2017 12.06.2018	2016 16.05.2017	2015 30.05.2016
Nettoomsætning	1.633.567
Bruttoresultat	-2.068.710	0	0	0	0	0
Resultat af primær drift	-7.563.628	0	-4.680.373	-3.743.964	-1.191.215	-88.911
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0
Finansielle indtægter	509	0	4.346	279	150	0
Finansieringsomkostninger	-166.967	0	-2.286	-2.004	-238	0
Andre finansielle omkostninger	0	0	0	0	0	0
Resultat før skat	-7.730.086	0	-4.678.313	-3.745.689	-1.191.303	-88.911
Resultat	-6.950.401	0	-3.999.207	-3.302.450	-944.010	-88.911
Forslag til udbytte	0	0	0	0	0	0

Aktiver

29.06.2021

Årsrapport	2020 29.06.2021	2018 08.04.2019	2017 12.06.2018	2016 16.05.2017	2015 30.05.2016
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.971.931	1.054.543	697.787	362.788	1.805
Likvider	3.203.763	254.474	2.467.736	1.097.134	227.679
Kortfristede aktiver	5.175.694	1.309.017	3.165.523	1.459.922	229.484
Immaterielle aktiver og goodwill	0	0	0	0	0
Finansielle anlægsaktiver	0	37.000	37.000	30.000	0
Materielle aktiver	70.719	0	0	0	0
Langfristede aktiver	70.719	37.000	37.000	30.000	0
Aktiver	5.246.413	1.346.017	3.202.523	1.489.922	229.484

Aktiver

29.06.2021

Passiver

29.06.2021

Årsrapport	2020 29.06.2021	2018 08.04.2019	2017 12.06.2018	2016 16.05.2017	2015 30.05.2016
Forslag til udbytte	0	0	0	0	0
Egenkapital	-358.964	374.023	2.874.629	1.281.679	-38.911
Hensatte forpligtelser	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0
Leverandører af varer og tjenesteydelser	44.722	222.175	33.077	167.917	0
Kortfristede forpligtelser	3.126.457	971.994	312.448	192.233	268.395
Gældsforpligtelser	5.605.377	971.994	327.894	208.243	268.395
Forpligtelser	5.605.377	971.994	327.894	208.243	268.395
Passiver	5.246.413	1.346.017	3.202.523	1.489.922	229.484

Passiver

29.06.2021

Nøgletal

29.06.2021

Årsrapport	2020 29.06.2021	2019 01.05.2020	2018 08.04.2019	2017 12.06.2018	2016 16.05.2017	2015 30.05.2016
Afkastningsgrad	-144,2 %	Na.	-347,7 %	-116,9 %	-80,0 %	-38,7 %
Dækningsgrad	-126,6 %	Na.	Na.	Na.	Na.	Na.
Resultatgrad	-425,5 %	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	1.936,2 %	Na.	-1.069,2 %	-114,9 %	-73,7 %	228,5 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-4.530,0 %	Na.	-204.740,7 %	-186.824,6 %	-500.510,5 %	Na.
Soliditestgrad	-6,8 %	Na.	27,8 %	89,8 %	86,0 %	-17,0 %
Likviditetsgrad	165,5 %	Na.	134,7 %	1.013,1 %	759,5 %	85,5 %

Resultat

29.06.2021

Gæld

29.06.2021

Årsrapport

29.06.2021

Nyeste:01.01.2020- 31.12.2020(offentliggjort: 29.06.2021)

Information om virksomhedens regnskabsklasse:The annual report of Drugstars ApS for 2020 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Oplysning om eventualaktiver:The Company has tax loss carry-forwards totalling DKK 14,757 thousand. The nominal value thereof is 22%, totalling DKK 3,246 thousand, which has not been recognised in the balance sheet due to the uncertainty as to application of the tax losses.

Beretning

29.06.2021

Dato for ledelsens godkendelse af årsrapporten:2021-06-24

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Going concern In Management's assessment, the Company has sufficient funds to meet its operational liquidity requirements through the end of August 2021. Management is working towards obtaining new and additional funding from current and potential new investors. Management believes that a new and additional financing round will be executed in due time prior to the end of August 2021 to secure funding to meet the Company's operational liquidity requirements at least through 31 December 2021. On this basis, Management presents the financial statements for 2020 on a going concern assumption. Due to the uncertainty associated with the completion of such financing round, significant uncertainties regarding going concern exist, and therefore the Company may be unable to realise its assets and discharge its liabilities in the normal course of business.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Drugstars ApS for the financial year 1 January - 31 December 2020.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The Company's principal activity is software development.